Correlation Between Akanda Corp and Supernus Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Akanda Corp and Supernus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Akanda Corp and Supernus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Akanda Corp and Supernus Pharmaceuticals, you can compare the effects of market volatilities on Akanda Corp and Supernus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Akanda Corp with a short position of Supernus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Akanda Corp and Supernus Pharmaceuticals.

Diversification Opportunities for Akanda Corp and Supernus Pharmaceuticals

-0.86
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Akanda and Supernus is -0.86. Overlapping area represents the amount of risk that can be diversified away by holding Akanda Corp and Supernus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Supernus Pharmaceuticals and Akanda Corp is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Akanda Corp are associated (or correlated) with Supernus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Supernus Pharmaceuticals has no effect on the direction of Akanda Corp i.e., Akanda Corp and Supernus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Akanda Corp and Supernus Pharmaceuticals

Given the investment horizon of 90 days Akanda Corp is expected to under-perform the Supernus Pharmaceuticals. In addition to that, Akanda Corp is 4.36 times more volatile than Supernus Pharmaceuticals. It trades about -0.08 of its total potential returns per unit of risk. Supernus Pharmaceuticals is currently generating about 0.06 per unit of volatility. If you would invest  2,729  in Supernus Pharmaceuticals on September 13, 2024 and sell it today you would earn a total of  956.00  from holding Supernus Pharmaceuticals or generate 35.03% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Akanda Corp  vs.  Supernus Pharmaceuticals

 Performance 
       Timeline  
Akanda Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Akanda Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Supernus Pharmaceuticals 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Supernus Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Akanda Corp and Supernus Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Akanda Corp and Supernus Pharmaceuticals

The main advantage of trading using opposite Akanda Corp and Supernus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Akanda Corp position performs unexpectedly, Supernus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will offset losses from the drop in Supernus Pharmaceuticals' long position.
The idea behind Akanda Corp and Supernus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets